Zephyr AI utilizes an AI-enabled platform that integrates diverse healthcare and biological data to identify optimal patient-drug matches and enhance clinical trial efficiency. This approach addresses the challenges of patient stratification and drug development costs, ultimately improving patient outcomes through personalized therapies.
Funding
$129.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug development and clinical trials face challenges in patient stratification, leading to increased costs, longer trial durations, and potential late-stage failures. Identifying the right patients for specific treatments and understanding the underlying biological mechanisms remain significant hurdles.
Solution
Zephyr AI offers an AI-enabled platform that integrates diverse healthcare and biological data to enhance patient-drug matching and improve clinical trial efficiency. The platform leverages the scale and diversity of available data to uncover insights that facilitate patient stratification and reveal biological context, accelerating the development of new drugs. By identifying patients most likely to benefit from specific treatments, the platform minimizes unnecessary interventions and supports the development of personalized therapies. The technology integrates with existing next-generation sequencing (NGS) data and platforms to deliver actionable insights for patient stratification without requiring customized assay development.
Target Audience
The primary target audience includes pharmaceutical companies, biotechnology firms, and clinical research organizations involved in drug development and clinical trials.
Features
- AI-enabled composite biomarkers for enhanced clinical development
- Patient stratification to identify individuals most likely to respond to specific treatments
- Identification of key molecular pathways to inform tailored drug combination design
- Integration with existing NGS data and platforms for seamless workflow integration
- Support for initiatives from early to late-stage clinical development
- Analysis of disease demographics and refinement of indications
- Implementation of adaptive trial designs
- Exploration of label expansion opportunities